MedTrace Logo

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

NCT03215277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2023-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Conditions

Interventions

DRUG

Bimekizumab

One bimekizumab dose will be administered.

DRUG

Certolizumab pegol

Two certolizumab pegol doses will be administered. One of these doses is a loading dose.

OTHER

Placebo

Placebo will be provided to maintain the blinding.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · +1-844-599-2273 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-04
Primary Completion
2020-05-25
Completion
2020-05-25
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Germany
  • Greece
  • Moldova
  • Netherlands
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03215277 on ClinicalTrials.gov